Trade Adverum Biotechn - ADVM CFD
Add to favourite- Summary
- Historical Data
Spread | 0.0580 | ||||||||
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.026235% | ||||||||
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.004012% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 0.1 | ||||||||
Currency | USD | ||||||||
Margin | 5.00% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
Prev. Close | 6.776 |
Open | 6.726 |
1-Year Change | 281.36% |
Day's Range | 6.566 - 6.736 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Sep 6, 2024 | 6.7260 | 0.0000 | 0.00% | 6.7260 | 6.7860 | 6.5360 |
Sep 5, 2024 | 6.7760 | 0.0300 | 0.44% | 6.7460 | 6.9260 | 6.6060 |
Sep 4, 2024 | 6.7260 | 0.0700 | 1.05% | 6.6560 | 6.9160 | 6.5360 |
Sep 3, 2024 | 6.7260 | -0.1500 | -2.18% | 6.8760 | 7.0760 | 6.6760 |
Aug 30, 2024 | 6.9060 | 0.1900 | 2.83% | 6.7160 | 6.9360 | 6.6760 |
Aug 29, 2024 | 6.8560 | -0.0300 | -0.44% | 6.8860 | 7.0260 | 6.7260 |
Aug 28, 2024 | 6.8960 | -0.2300 | -3.23% | 7.1260 | 7.1260 | 6.5560 |
Aug 27, 2024 | 7.1960 | -0.1800 | -2.44% | 7.3760 | 7.3760 | 7.0360 |
Aug 26, 2024 | 7.4260 | 0.1300 | 1.78% | 7.2960 | 7.5060 | 7.1160 |
Aug 23, 2024 | 7.2660 | 0.3500 | 5.06% | 6.9160 | 7.3060 | 6.9060 |
Aug 22, 2024 | 7.0260 | -0.0700 | -0.99% | 7.0960 | 7.1160 | 6.7860 |
Aug 21, 2024 | 7.1460 | 0.3500 | 5.15% | 6.7960 | 7.1660 | 6.7960 |
Aug 20, 2024 | 6.8860 | -0.1500 | -2.13% | 7.0360 | 7.2860 | 6.8860 |
Aug 19, 2024 | 7.1960 | 0.6100 | 9.26% | 6.5860 | 7.2860 | 6.5860 |
Aug 16, 2024 | 6.7960 | 0.3200 | 4.94% | 6.4760 | 6.8660 | 6.3860 |
Aug 15, 2024 | 6.5060 | 0.0900 | 1.40% | 6.4160 | 6.6560 | 6.3860 |
Aug 14, 2024 | 6.4260 | -0.3100 | -4.60% | 6.7360 | 6.7360 | 6.3360 |
Aug 13, 2024 | 6.7060 | 0.2300 | 3.55% | 6.4760 | 6.9160 | 6.4760 |
Aug 12, 2024 | 6.4260 | -0.0500 | -0.77% | 6.4760 | 6.6060 | 6.3360 |
Aug 9, 2024 | 6.5360 | -0.2600 | -3.83% | 6.7960 | 6.9760 | 6.5260 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Adverum Biotechn Company profile
About Adverum Biotechnologies Inc
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company targeting ocular and rare diseases. It develops gene therapy product candidates. Its ADVM-022, is a clinical-stage gene therapy product candidate developed for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME). ADVM-022, is given as a one-time in-office intravitreal (IVT) injection and is designed to reduce the burden of anti-vascular endothelial growth factor (anti-VEGF) injections, optimize patient compliance and improve vision outcomes for patients with wet AMD or DME. It is conducting the OPTIC trial, designed as a multi-center, open-label, Phase I, dose-ranging safety trial of ADVM-022 in patients with wet AMD, who have demonstrated responsiveness to anti-VEGF treatment. It is also conducting the INFINITY trial, a multi-center, Phase II, randomized, double-masked, active comparator-controlled study evaluating a single IVT injection of ADVM-022 in patients with DME.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Adverum Biotechnologies Inc revenues increased from $0K to $7.5M. Net loss increased 39% to $111.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General and administrative - Balancing increase of 74% to $37.8M (expense), Research and development -gross increase of 31% to $59.5M (expense).
Industry: | Bio Therapeutic Drugs |
100 Cardinal Way
REDWOOD CITY
CALIFORNIA 94063
US
News
![](https://img.capital.com/imgs/articles/192x130x1/1350x880_-HP-_Newsquawk-light.png)
Introducing Newsquawk: your new in-platform newsfeed
We are very excited to announce the launch of Newsquawk in the Capital.com platform and app. This new newsfeed is designed to help you get ahead with real-time headlines, personalised stories and in-depth reports – all available directly in the platform and app, where you need them.
14:09, 20 August 2024![](https://img.capital.com/imgs/articles/192x130x1/Gold_10.jpg)
Jackson Hole Preview: All eyes on Powell and Gold
The key focus this week will be on Jerome Powell and any insight he may give into the future of monetary policy.
15:24, 19 August 2024![](https://img.capital.com/imgs/articles/192x130x1/USUK.jpg)
All eyes on inflation: US and UK CPI take centre stage
Just over a month has gone by since the latest CPI data was released in the US and so much has happened since.
14:41, 13 August 2024![](https://img.capital.com/imgs/articles/192x130x1/European-stocks_0.jpg)
European stocks face resistance in their attempt to recover
European stocks struggle to recover as the tech sector faces continued downside pressure in Asia.
13:56, 9 August 2024![](https://img.capital.com/imgs/articles/192x130x1/Global-selloff_0.jpg)
Global selloff continues on US economy fears
Thursday’s rise in jobless claims led to a market meltdown in the US stock market as investors became concerned that the Federal Reserve made the wrong decision by keeping rates unchanged on Wednesday.
14:40, 5 August 2024![](https://img.capital.com/imgs/articles/192x130x1/Graphiccs-1-.png)
FOMC PREVIEW
Markets believe the Federal reserve will continue to leave their monetary policy unchanged at the meeting next week.
14:09, 1 August 2024![](https://img.capital.com/imgs/articles/192x130x1/Risk-Management-in-Trading.png)
How to manage risk when trading
Learn what risk management is and find out how understanding about it could help you identify potential risks in your investment portfolio. Find out more.
06:57, 22 July 2024People also watch
Still looking for a broker you can trust?
Join the 640,000+ traders worldwide that chose to trade with Capital.com